Riboflavin Uva
Riboflavin Uva - Related Videos
05:56
Scleral Cross-linking Using Riboflavin and Ultraviolet-A Radiation for Prevention of Axial Myopia in a Rabbit Model
0 Views •
Cited by 27 •
2016
We demonstrate the effect of scleral crosslinking with riboflavin and UVA on an axial elongation rabbit eye. Axial elongation was induced in 13 day-old New Zealand rabbits (male and female) by suturing their right eye eyelids (tarsorrhaphy).
05:09
A Riboflavin and UV Light Treatment of Platelet Products to Eliminate Bacteria
0 Views •
2025
This video demonstrates the riboflavin and UV light-based pathogen reduction process against high-titer bacterial contamination in human platelet products. This process could help to lower the risk of severe adverse transfusion events associated with bacterial contamination.
10:32
Treatment of Platelet Products with Riboflavin and UV Light: Effectiveness Against High Titer Bacterial Contamination
0 Views •
Cited by 19 •
2015
The storage conditions of platelet products create an ideal environment for bacterial contaminants to multiply to dangerous levels. The goal of this study was to use a colony forming assay to evaluate a riboflavin based pathogen reduction process against high titer bacterial contamination in human platelet products.
07:29
Three Different Protocols of Corneal Collagen Crosslinking in Keratoconus: Conventional, Accelerated and Iontophoresis
0 Views •
Cited by 30 •
2015
Corneal collagen cross-linking (CXL) is the only conservative treatment currently available to halt keratoconus progression by improving the biomechanical rigidity of the corneal stroma. The aim of this manuscript is to highlight the methods of three different protocols of CXL: conventional CXL (C-CXL), accelerated CXL (A-CXL), and iontophoresis CXL (I-CXL).
08:25
Inactivation of Pathogens via Visible-Light Photolysis of Riboflavin-5′-Phosphate
0 Views •
Cited by 3 •
2022
Here, we present a protocol to inactivate pathogenic bacteria with reactive oxygen species produced during photolysis of flavin mononucleotide (FMN) under blue and violet light irradiation of low intensity. FMN photolysis is demonstrated to be a simple and safe method for sanitary processes.
FAQs
Riboflavin’s key role is to make UVA exposure biologically effective. It penetrates corneal tissue and functions as a photosensitizer, meaning it responds to the applied light. This enables the light exposure to initiate the chemical events needed for collagen cross-link formation. Its delivery is therefore central to whether the intended strengthening response can occur.
UVA does not provide strengthening simply through illumination. After riboflavin is activated, the process generates reactive oxygen species, chemically reactive molecules that promote additional bonds between collagen fibers. Those bonds change the tissue’s mechanical behavior, providing the molecular explanation for increased corneal stiffness rather than a temporary optical effect.
In weakened corneal tissue, greater stiffness helps the cornea better resist changes in shape. That mechanical effect is clinically relevant because keratoconus and other corneal ectasias can compromise corneal geometry and visual function. The intended benefit is preservation of corneal shape and slowing disease progression, not merely exposure to UVA.
Research focuses on irradiation conditions, riboflavin delivery, and patient selection because each can influence how consistently the cornea receives the intended photochemical stimulus. Studying these variables helps researchers optimize treatment protocols for different clinical situations and therapeutic goals, rather than treating the intervention as a single fixed recipe.
At a broad procedural level, treatment requires riboflavin to penetrate the cornea and UVA irradiation to activate the photosensitizer. The resulting photochemical response promotes additional bonds between collagen fibers and strengthens the tissue. Exact riboflavin-delivery and irradiation conditions remain important protocol considerations because they determine how the treatment is applied.
The treatment is used primarily to slow progression of keratoconus and other forms of corneal ectasia. It is especially relevant when preserving corneal shape and visual function is an objective. The approach also supports research into optimized protocols, including riboflavin delivery, UVA irradiation conditions, and selection of patients most appropriate for treatment.